VIRACTA
Live / Registered — Registered (as of 09 Apr 2024)
What this means for you
Registered since 09 Apr 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97457119
- Registration number
- 7356577
- Mark type
- Word mark
- Filed
- 14 Jun 2022
- Published for opposition
- 30 May 2023
- Registered
- 09 Apr 2024
- Attorney of record
- Alyssa M. Worsham
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and therapeutic preparations for the treatment of patients with viral-associated cancers and other viral associated diseases and disorders; pharmaceutical products, namely, pharmaceutical products for treating cancer; pharmaceutical products for treating viral infections; pharmaceutical products for immune reconstitution; pharmaceutical products for cell-based immunotherapy; pharmaceutical products for T-cell adoptive transfer; pharmaceutical products for cellular adoptive transfer; pharmaceutical preparations for the treatment of cancer, tumors, and hematological malignancies; all of the foregoing containing antivirals
- Class 042 — Scientific and technological services: Development of pharmaceutical preparations and medicines; drug discovery services; pharmaceutical drug development services; research relating to medicines in the nature of pharmaceutical research; medical research; pharmaceutical research and development services; medical research services in the field of cancer, viral-associated cancers and other viral associated diseases and disorders; research and development of biological and chemical preparations for the treatment of cancer, viral-associated cancers and other viral associated diseases and disorders; research and development of pharmaceutical products, preparations and compounds for the treatment of viral-associated cancers and other viral associated diseases and disorders; DNA screening and analysis services for scientific research purposes; research and development of pharmaceutical products, preparations and compounds for T-cell adoptive transfer, immune reconstitution, and cell-based immunotherapy; research and development of pharmaceutical products, preparations and compounds for the treatment of cancer, tumors, and hematological malignancies
- Class 044 — Medical, beauty and agricultural services: Providing medical information, consultancy and advisory services; providing a website via a global computer network featuring medical information in the fields of cancer, viral-associated cancers and other viral associated diseases and disorders
Owner
- Viracta Therapeutics, Inc., Cardiff, CA, US
- Viracta Therapeutics, Inc., Cardiff, CA, US
- Viracta Therapeutics, Inc., Cardiff, CA, US
Prior registrations
Prosecution history
- 29 Jan 2025 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 09 Apr 2024 — REGISTERED-PRINCIPAL REGISTER
- 09 Apr 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 06 Mar 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 05 Mar 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 05 Feb 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 16 Jan 2024 — USE AMENDMENT FILED
- 05 Feb 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 16 Jan 2024 — TEAS STATEMENT OF USE RECEIVED
- 25 Jul 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 May 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 May 2023 — PUBLISHED FOR OPPOSITION
- 10 May 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 26 Apr 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Apr 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED